BIO's first annual report on diversity in the workplace found room for improvement, as biotech workforces - especially at the executive level - were found to not represent the U.S. population. The report was based on a survey of nearly 100 companies in late spring 2019.
Experts at last week's BIO meeting in Philadelphia discussed the long-term implications of many gene therapies hitting the market, and ways their prices could be lowered so they'd be more cost-effective.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
At BIO Tuesday, panelists discussed the lack of racial, ethnic and gender diversity in clinical trials and its potential implications.
One attendee called the PABNAB party entertainment "tone-deaf," but it's not the first event of its kind at a biotech show.
It’s an incredible time for the life sciences, panelists at a Biotech Showcase session on Monday agreed. However, it comes with a catch: The greater the miracle, the greater the anguish when a patient can’t afford or can’t access the drug.
At the sixth annual BIO Patient and Health Advocacy Summit in Washington, D.C. this week, a discussion on clinical trial design explored some of the challenges of ensuring patient's needs are balanced with those of drug developers and regulatory needs.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Drug pricing was destined to be a major topic, as manufacturers and payers continue to duke it out.
So where are we with CAR-T? Is it the innovative, transformative, disruptive, paradigm-changing cancer therapy we all hope for, or is it another incremental improvement?
Muhammad Ali announced many years ago that he suffered from Parkinson’s disease, but Dr. Bennet Omalu thinks differently, hypothesizing the boxer may have suffered from CTE.
Janelle R. Anderson, PhD, Managing Partner of CTI Life Sciences Fund, has started a new podcast in which she interviews business leaders within the life sciences and venture capital.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Martin Shkreli attracted a legion of negative attention from the masses thanks to his drug price hikes - and less-than-winsome persona. But can we learn something from this?
There's that Eminem mentality Martin has tweeted so much about.
Can we think of a less innovative word these days than "innovative?" BIO doesn't seem to care, given its hackneyed new name change.
How are venture capital dollars are actually disseminated? Into early stage companies? Late? What fields get the most investment – cancer? Bruce Booth of Atlas Ventures blogged about this today on his Life Sci VC site about this topic, highlighted in a new whitepaper from BIO. Here are the highlights: -Nearly 80 percent of U.S. venture […]
Good news (or is it?): The average U.S. Food and Drug Administration drug review time is at its lowest point this century. A handy chart from the California Healthcare Institute and Boston Consulting Group released today at BIO 2014 in San Diego highlights the precipitous drop in the time of review and approval of drugs. […]